C-suite barometer: life sciences and pharmaceuticals sector view

In a year marked by global uncertainty, shifting regulations and fast-moving innovation, leaders in the life sciences and pharmaceuticals sector are redefining their strategic priorities. Drawing on insights from executives from across more than 35 countries, our latest report captures how sector players are navigating complexity, investing in growth and positioning themselves for long-term success in a competitive landscape.

Featuring commentary from our Forvis Mazars experts and contributors including Damien Catoir, Servier, and Cédric Moreau, Sofinnova Partners, the report provides a valuable benchmark for sector players looking to navigate a rapidly-evolving landscape.

The Korean pharmaceutical and biotechnology industry shares similar growth directions and challenges with the global market. In particular, Korea is strengthening its global competitiveness through innovation and technology-driven strategies. However, ensuring supply chain stability, enhancing ESG compliance, and accelerating digital transformation will be crucial strategic priorities for sustaining long-term growth in the sector.
Jung Min Lee Partner, Audit & assurance

Key findings

Most leaders (98%) in the sector have a positive outlook for their businesses in 2025.
Increased competition (55%) and supply chain restrictions (47%) are listed as the top factors holding back growth for C-suite executives.
Economic factors were identified as having the biggest impact on businesses by 39% of leaders, with 37% viewing the emergence of technologies as significant.

Looking ahead, executives have outlined three core strategic priorities for 2025 and beyond: entering new products and services, transformation through company IT and technology, and international expansion.

Explore the full findings and discover how sector leaders are preparing for growth in a complex and competitive environment.